Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Protocol Providing Pegylated-interferon Alfa-2a (PEGASYS®) as Monotherapy or in Combination With Ribavirin (COPEGUS®) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

NCT00800735 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00800735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00800735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Protocol Providing Pegylated-interferon Alfa-2a (PEGASYS®) as Monotherapy or in Combination With Ribavirin (COPEGUS®) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2009
Completion date
March 31, 2012
Enrollment
30 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic